In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Oral GLP-1 Be More than Just Convenient?

Executive Summary

Given the collapse of all the inhaled insulin collaborations, many observers are skeptical that the Novo/Emisphere collaboration to create an oral version of Novo's liraglutide GLP-1 -- the drug-delivery company's biggest deal ever -- will work out any better. GLP-1, however, doesn't have all the baggage of insulin therapy, so there is in fact better logic for an oral pill's success. Still, if the program creates merely an oral version of once-a-day liraglutide, with no clinical advantages over its GLP-1 competitors, it will die just as certainly as did inhaled insulin.
Advertisement

Related Content

Enject's GlucaPen: Mightier than the Hypo-kit?
Enject's GlucaPen: Mightier than the Hypo-kit?
Enject's GlucaPen: Mightier than the Hypo-kit?
Inhaled Insulin is Dead. Long Live Inhaled Insulin
Inhaled Insulin is Dead. Long Live Inhaled Insulin
Insulin Delivery: Still Waiting to Exhale
Exubera's Problem: It's Still Just Insulin

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel